Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Avutometinib potassium by Verastem for Metastatic Melanoma: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Metastatic Melanoma. According to GlobalData, Phase...
Avutometinib potassium by Verastem for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Avutometinib potassium by Verastem for Fallopian Tube Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Fallopian Tube Cancer. According to GlobalData,...
Avutometinib potassium by Verastem for Peritoneal Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Peritoneal Cancer. According to GlobalData, Phase...
Avutometinib potassium by Verastem for Ovarian Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Pre-Registration for Ovarian Cancer. According to GlobalData, Pre-Registration drugs...
Avutometinib potassium by Verastem for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
Avutometinib potassium by Verastem for Gastroesophageal (GE) Junction Carcinomas: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Gastroesophageal (GE) Junction Carcinomas. According to...
Avutometinib potassium by Verastem for Metastatic Pancreatic Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData,...
Avutometinib potassium by Verastem for Peritoneal Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Phase III for Peritoneal Cancer. According to GlobalData, Phase...
Avutometinib potassium by Verastem for Ovarian Cancer: Likelihood of Approval
Avutometinib potassium is under clinical development by Verastem and currently in Pre-Registration for Ovarian Cancer. According to GlobalData, Pre-Registration drugs...